top of page

Everest Medicines and Shanghai Pharma Unite to Speed Up XERAVA's Market Reach in China

Everest Medicines, a trailblazer in the biopharmaceutical realm, recently declared its alliance with Shanghai Pharma subsidiary, SPH Keyuan Xinhua Pharmaceutical Co., Ltd. (SPH Kyuan), in a strategic partnership aimed at accelerating the commercialization of XERAVA in mainland China.

Memorandum of Understanding (MoU) - Everest and SPH Kyuan

A Memorandum of Understanding (MoU) was signed between Everest Medicines and SPH Kyuan, setting the foundation for their future collaboration. The primary objective of this partnership is to enhance the import and channel distribution of XERAVA (eravacycline) in China.

"We are very excited to reach a partnership with SPH Kyuan. SPH Kyuan's rich experience in drug import and channel distribution will accelerate the delivery of XERAVA to hospitals and patients in need," - Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.

Advantages of the Partnership

SPH Kyuan's remarkable position in drug import, extensive distribution network, and modern logistics system is expected to boost the scale and speed of commercialization of XERAVA, ultimately benefiting patients and addressing urgent medical needs in China.

XERAVA - A Revolutionary Drug

XERAVA (eravacycline) is a novel, fully synthetic, fluorocycline intravenous antibiotic. Approved by the National Medical Products Administration (NMPA) of China for the treatment of complicated intra-abdominal infections (cIAI) in adult patients, XERAVA is recommended by multiple treatment guidelines in China and globally for its broad bacterial spectrum coverage and high potency against multidrug-resistant bacterial infections.

# XERAVA properties
bacterial_spectrum_coverage = "broad"
potency = "high"

Launch Plans for XERAVA

Everest has planned to commercially launch XERAVA in mainland China in the third quarter of this year.

"This partnership marks another step towards the successful commercialization of XERAVA, leading our pipeline with at least three more products expected to be approved in the next two years." - Rogers Yongqing Luo, CEO of Everest Medicines.

SPH Kyuan's Perspective

"We are honored to reach a strategic pact with Everest around XERAVA, which will leverage the strengths of both parties," expressed Yu Rui, general manager of SPH Kyuan.

Everest's Future Plans

Apart from XERAVA, Everest is also actively developing other essential innovative treatment options in the infectious disease space. These include taniborbactam, which is planned to be filed for NDA in China this year for complicated urinary tract infection, and EVER206, a novel polymyxin derivative with a potentially robust safety profile, expected to initiate phase III clinical study in the second half of this year.

Everest Medicines - An Overview

Everest Medicines is a biopharmaceutical company committed to developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines. These address critical unmet medical needs for patients in Asian markets. With a management team having deep expertise from leading global pharmaceutical companies and local Chinese pharmaceutical companies, Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in renal diseases, infectious diseases, and autoimmune disorders.


This partnership is a significant step towards addressing the severe problem of drug-resistant bacteria infections in China and overseas. With the help of innovative drugs like XERAVA, Everest Medicines and SPH Kyuan aim to alleviate the economic and healthcare burdens posed by these infections, benefiting countless patients in need.


Recent Posts

See All

Biogen's Acquisition of Reata Pharmaceuticals

Introduction In a significant development for the medical community, Biogen Inc. (Nasdaq: BIIB) has announced its definitive agreement to acquire Reata Pharmaceuticals, Inc. (Nasdaq: RETA). This strat


bottom of page